Windlas Biotech Limited (NSE:WINDLAS)

India · Delayed Price · Currency is INR

884.50

+8.30 (0.95%)

Apr 21, 2026, 2:16 PM IST

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018
Pharmaceuticals	7.60B	6.31B	5.13B	4.66B	4.28B
Pharmaceuticals Growth	20.43%	22.97%	10.12%	8.96%	30.03%
Total	7.60B	6.31B	5.13B	4.66B	4.28B
Total Growth	20.43%	22.97%	10.12%	8.96%	30.03%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	Mar '19 Mar 31, 2019	Mar '18 Mar 31, 2018
India	7.22B	6.01B	4.91B	4.42B	4.08B
India Growth	20.12%	22.57%	10.92%	8.52%	28.32%
outside India	326.32M	273.91M	198.43M	209.35M	189.95M
outside India Growth	19.13%	38.04%	-5.22%	10.21%	77.72%
Total	7.55B	6.29B	5.11B	4.63B	4.27B
Total Growth	20.07%	23.17%	10.19%	8.59%	29.92%

Source: S&P Global Market Intelligence.